Related references
Note: Only part of the references are listed.Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States
Pareen Vora et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2022)
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Gerhard Hindricks et al.
EUROPEAN HEART JOURNAL (2021)
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases
Patrick G. Northup et al.
HEPATOLOGY (2021)
Spotlight: Management of Coagulation Disorders in Patients With Cirrhosis
Perica Davitkov et al.
GASTROENTEROLOGY (2021)
Nonalcoholic fatty liver disease and the risk of atrial fibrillation stratified by body mass index: a nationwide population-based study
So-Ryoung Lee et al.
SCIENTIFIC REPORTS (2021)
Non-alcoholic fatty liver disease - a procoagulant condition?
Lucija Virovic-Jukic et al.
CROATIAN MEDICAL JOURNAL (2021)
ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation
Douglas A. Simonetto et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review
Stefano Ballestri et al.
ADVANCES IN THERAPY (2020)
Anticoagulant therapy for splanchnic vein thrombosis ISTH SSC Subcommittee Control of Anticoagulation
Marcello Di Nisio et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
The Association between Nonalcoholic Fatty Liver Disease and Stroke: Results from the Korean Genome and Epidemiology Study (KoGES)
Yun-Jung Yang et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)
Direct Oral Anticoagulants in Chronic Liver Disease
Taylor D. Steuber et al.
ANNALS OF PHARMACOTHERAPY (2019)
AGA Clinical Practice Update: Coagulation in Cirrhosis
Jacqueline G. O'Leary et al.
GASTROENTEROLOGY (2019)
Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease
So-Ryoung Lee et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Anticoagulation in the cirrhotic patient
Laura Turco et al.
JHEP REPORTS (2019)
Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis
Jianping Hu et al.
ONCOTARGET (2018)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Oral Anticoagulation in Patients With Liver Disease
Arman Qamar et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Direct oral anticoagulants in patients with liver cirrhosis: A systematic review
Evert Willian Hoolwerf et al.
THROMBOSIS RESEARCH (2018)
Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases
Guadalupe Garcia-Tsao et al.
HEPATOLOGY (2017)
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
Andreas Zirlik et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2017)
Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation
Shang-Hung Chang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin
W. C. Y. Lau et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Liver Cirrhosis in Patients With Atrial Fibrillation: Would Oral Anticoagulation Have a Net Clinical Benefit for Stroke Prevention?
Ling Kuo et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis
Toufik Mahfood Haddad et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2017)
Anticoagulation in cirrhosis: a new paradigm?
Filippo Leonardi et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2017)
Thrombelastography-Guided Blood Product Use Before Invasive Procedures in Cirrhosis With Severe Coagulopathy: A Randomized, Controlled Trial
Lesley De Pietri et al.
HEPATOLOGY (2016)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Francois Laliberte et al.
ADVANCES IN THERAPY (2015)
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)
Sameer Bansilal et al.
AMERICAN HEART JOURNAL (2015)
Hepatotoxicity of New Oral Anticoagulants (NOACs)
Evangelia Liakoni et al.
DRUG SAFETY (2015)
Causes and Consequences of Portal Vein Thrombosis in 1,243 Patients With Cirrhosis: Results of a Longitudinal Study
Filipe Nery et al.
HEPATOLOGY (2015)
Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial
Joshua N. Goldstein et al.
LANCET (2015)
Stratifying the Risks of Oral Anticoagulation in Patients With Liver Disease
Lydia M. Efird et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2014)
Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis
Daniel Caldeira et al.
HEART (2014)
Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis
Jung Wha Chung et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2014)
Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis
Maria Gabriela Delgado et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)
Christian T. Ruff et al.
AMERICAN HEART JOURNAL (2010)
Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
Renato D. Lopes et al.
AMERICAN HEART JOURNAL (2010)
Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
Michael D. Ezekowitz et al.
AMERICAN HEART JOURNAL (2009)
Prevention and management of Gastroesophageal varices and variceal Hemorrhage in cirrhosis
Guadalupe Garcia-Tsao et al.
HEPATOLOGY (2007)
Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management
Stephen H. Caldwell et al.
HEPATOLOGY (2006)
Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity
T Lisman et al.
HEPATOLOGY (2006)
Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: A Cochrane meta-analysis
G D'Amico et al.
GASTROENTEROLOGY (2003)
Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis
GV Papatheodoridis et al.
GUT (2003)
Share Paper
